Abstract
Cancer and Cardiovascular Disease: The Complex Labyrinth.
Highlights
In 2005 trastuzumab in combination with chemotherapy was shown to significantly improve disease-free and overall survival in women with early stage HER2 positive breast cancer [6, 7]
We have known for years that cancer drugs, such as the anthracyclines, can cause severe and permanent heart damage including heart failure (HF)
While the dramatic improvements in clinical outcomes led to the widespread adoption of this treatment in clinical practice, it became readily apparent that women were experiencing higher rates of cardiac dysfunction than had been anticipated during clinical development— placing oncologists in a difficult situation—to treat or not to treat [8]!
Summary
In 2005 trastuzumab in combination with chemotherapy was shown to significantly improve disease-free and overall survival in women with early stage HER2 positive breast cancer [6, 7]. Susan Dent,1 Peter Liu,2 Christine Brezden-Masley,3 and Daniel Lenihan4 Cardiotoxicity, a relatively new term in the medical literature, refers to the impact of cancer therapies on the heart and cardiovascular system [3, 4].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
